If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenflow Biosci Regulatory News (GENF)

Share Price Information for Genflow Biosci (GENF)

Share Price is delayed by 15 minutes
Get Live Data
2.05    0.05 (2.50%)
Bid:
2.00
Ask:
2.10
Spread: 0.10 (5.00%)
Market Cap: £11.61m
GENF Live PriceLast checked at - London Stock Exchange

Intraday Genflow Biosci Share Chart

Holding in Company

28 Mar 2025 07:10

RNS Number : 5931C
Genflow Biosciences PLC
28 March 2025
 

 

 

1. Issuer Details

ISIN

GB00BP2C3V08

Issuer Name

GENFLOW BIOSCIENCES PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

MR ERIC LEIRE

City of registered office (if applicable)

15 Ingestre Place,

Country of registered office (if applicable)

UK

Name

City of registered office

Country of registered office

Eric Leire

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

27-Mar-2025

6. Date on which Issuer notified

27-Mar-2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

36.180000

0.000000

36.180000

126514999

Position of previous notification (if applicable)

35.600000

0.000000

35.600000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BP2C3V08

126514999

36.180000

Sub Total 8.A

126514999

36.180000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

 27-Mar-2025

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLDZGZFLNMGKZM
Date   Source Headline
29th Jun 202612:02 pmRNSResult of AGM
22nd Jun 20267:00 amRNS-RParticipation at BIO International Convention 2026
17th Jun 20267:00 amRNSCompany to present at Animal Longevity Summit 2026
4th Jun 20267:00 amRNSNotice of AGM
8th May 202610:07 amRNSExercise of Warrants and Issue of Equity
30th Apr 20261:12 pmRNSFinal Results
28th Apr 20267:00 amRNSExpansion of Confidentiality Agreements
20th Apr 20267:00 amRNS-RStrategic Technology Collaboration
13th Apr 20267:00 amRNSInternational Patent Publication
8th Apr 20268:55 amRNS-RUpdate on the Dog Study
31st Mar 20267:00 amRNSTotal Voting Rights
5th Mar 202610:55 amRNSIssue of Equity & PDMR Notifications
2nd Mar 202612:30 pmRNSResult of GM
2nd Mar 20267:00 amRNSReceipt of First Tranche of Grant
12th Feb 20267:00 amRNSPreliminary Interim Results From Dog Study
11th Feb 20267:00 amRNSNotice of GM
30th Jan 202612:29 pmRNSHolding(s) in Company
28th Jan 20267:00 amRNSAdministrative Approval of Grant & 2026 Priorities
19th Jan 20267:00 amRNSDirectorate change
8th Jan 20267:00 amRNS-RReview of 2025
16th Dec 20257:00 amRNSCompletion of Dosing Phase of Canine Gene Therapy
11th Dec 20257:00 amRNS-RGenflow to Attend Healthcare Conference
31st Oct 20257:00 amRNSTotal Voting Rights
24th Oct 20257:00 amRNSHolding(s) in Company
22nd Oct 20257:00 amRNSSecond European Patent Application
20th Oct 20257:00 amRNSRecognition of Patentability of Claims
10th Oct 20257:00 amRNSUpdate on Animal Health Program
9th Oct 20257:00 amRNSUpdate, Equity Issue and PDMR Notification
2nd Oct 202512:37 pmRNSIssue of Equity - Correction
2nd Oct 20257:59 amRNSIssue of Equity
30th Sep 20257:00 amRNSHalf-year Report
19th Sep 202512:40 pmRNSHolding(s) in Company
19th Sep 20257:00 amRNS-RGenflow Strengthens IP Portfolio
15th Sep 20257:00 amRNS-RGenflow Signs CDAs with Animal Health Companies
27th Aug 20253:07 pmRNSHolding(s) in Company
18th Aug 20257:00 amRNS-RCompany Update on Dog Trials
24th Jul 20257:00 amRNS-RClinical Readiness Acceleration
17th Jul 20257:00 amRNSGenflow Confirms Progression of Grant
17th Jun 20257:00 amRNS-RCorporate Update
12th Jun 202510:16 amRNSResult of AGM
30th May 20253:20 pmRNSTotal Voting Rights
28th May 20257:00 amRNS-RGenflow Signs Master Services Agreement
22nd May 202510:51 amRNSAGM Notice
15th May 20257:00 amRNS-RKey SIRT6 Patent Application
12th May 202510:50 amRNSHolding(s) in Company
9th May 20257:00 amRNSShare Subscription, Director's Dealing and Update
30th Apr 20253:29 pmRNSFinal Results
14th Apr 20257:00 amRNS-RLaunch of AI-Powered Partnership
10th Apr 20257:00 amRNS-RGenflow Launches New Development Program
28th Mar 20257:10 amRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.